At ENYO Pharma, patients with impaired kidney function are in the center of our discussions.
We are committed every day to develop new therapeutics for improving the quality of life of patients with Alport syndrome. Working closely with our patient advocacy partners, as key players as representatives of patients, families and caregivers, support our best strategy for clinical study development in Alport syndrome.
ALPESTRIA-1 clinical trial
We are aiming to preserve kidney function and reverse kidney damage with the investigational drug Vonafexor tested in our Phase 2 clinical study named “ALPESTRIA-1”.
